Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Atrial Fibrillation | Research

Association between the Triglyceride–Glucose Index and Non-Alcoholic Fatty Liver Disease in patients with Atrial Fibrillation

Authors: Xiaozhong Li, Fenfang Zhan, Tian Peng, Zhen Xia, Juxiang Li

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

The triglyceride and glucose index (TyG), as a surrogate of insulin resistance (IR), is closely associated with non-alcoholic fatty liver disease (NAFLD). However, the association between the TyG index and NAFLD in atrial fibrillation (AF) is unknown. Therefore, the purpose of this study is to explore the association between the TyG index and NAFLD in AF.

Methods

This retrospective study was performed at Nanchang University’s Second Affiliated Hospital. The AF patients who were hospitalized from January 2021 to December 2022 were enrolled. The association between the TyG index and NAFLD in AF patients was assessed by logistic regression and restricted cubic spline analysis. The ability of TyG index for identifying NAFLD was estimated by the area under the receiver operating characteristic (ROC).

Results

In this study, 632 people participated in the final analysis, with 176 (27.84%) having NAFLD. In the full adjustment model, there is an association between the TyG index and NAFLD [per 1 unit increment; odds ratios (ORs): 3.28; 95% confidence interval (CI) 2.14, 5.03]. Compared to the lowest tertile (TyG index < 8.29), the ORs for the highest tertile (TyG index ≥ 8.82) were 4.15 (95%CI: 2.28, 7.53). Dose–response analysis showed that the TyG index and NAFLD have a nearly linear relationship (P non-linear = 0.71). The area under the curve (AUC) of the TyG index is 0.735.

Conclusions

Our findings showed a significant association between the TyG index and NAFLD. The TyG index may be a good marker for predicting NAFLD in AF patients.

Available only for authorised users

Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–24. https://doi.org/10.1016/s0140-6736(20)32511-3.CrossRefPubMed

Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109.CrossRefPubMed

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.CrossRefPubMed

Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70(4):1119–33. https://doi.org/10.1002/hep.30702.CrossRefPubMed

Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019;3(11):1459–71. https://doi.org/10.1002/hep4.1419.CrossRefPubMedPubMedCentral

Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):425–39. https://doi.org/10.1038/s41575-018-0010-0.CrossRefPubMed

Mantovani A, Dauriz M, Sandri D, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 2019;39(4):758–69. https://doi.org/10.1111/liv.14044.CrossRefPubMed

Jaiswal V, Ang SP, Huang H, et al. Association between nonalcoholic fatty liver disease and atrial fibrillation and other clinical outcomes: a meta-analysis. J Investig Med. 2023. https://doi.org/10.1177/10815589231164777.CrossRefPubMed

Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528. https://doi.org/10.1161/cir.0000000000000659.CrossRefPubMed

10.

Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–37. https://doi.org/10.1007/s00392-020-01709-7.CrossRefPubMed

11.

Sun X, Chen Y, Zeng Q, Huang X, Cai J. Reduction of leukocyte-derived H(2)S linked to abnormal glycolipid metabolism in hypertensive subjects. Clin Exp Hypertens. 2017;39(5):427–34. https://doi.org/10.1080/10641963.2016.1267193.CrossRefPubMed

12.

Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21113863.CrossRefPubMedPubMedCentral

13.

Vasques AC, Novaes FS, de Oliveira MS, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98–100. https://doi.org/10.1016/j.diabres.2011.05.030.CrossRefPubMed

14.

Zhang S, Du T, Zhang J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):15. https://doi.org/10.1186/s12944-017-0409-6.CrossRefPubMedPubMedCentral

15.

Song S, Son DH, Baik SJ, Cho WJ, Lee YJ. Triglyceride glucose–waist circumference (TyG–WC) is a reliable marker to predict non-alcoholic fatty liver disease. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10092251.CrossRefPubMedPubMedCentral

16.

Hu L, Bao H, Huang X, et al. Relationship between the triglyceride glucose index and the risk of first stroke in elderly hypertensive patients. Int J Gen Med. 2022;15:1271–9. https://doi.org/10.2147/ijgm.S350474.CrossRefPubMedPubMedCentral

17.

Wang C, Cai Z, Deng X, et al. Association of hepatic steatosis index and fatty liver index with carotid atherosclerosis in type 2 diabetes. Int J Med Sci. 2021;18(14):3280–9. https://doi.org/10.7150/ijms.62010.CrossRefPubMedPubMedCentral

18.

Davidson KW, Barry MJ, Mangione CM, et al. Screening for atrial fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(4):360–7. https://doi.org/10.1001/jama.2021.23732.CrossRefPubMed

19.

Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. https://doi.org/10.1186/s12902-022-00980-1.CrossRefPubMedPubMedCentral

20.

Huang R, Cheng Z, Jin X, et al. Usefulness of four surrogate indexes of insulin resistance in middle-aged population in Hefei, China. Ann Med. 2022;54(1):622–32. https://doi.org/10.1080/07853890.2022.2039956.CrossRefPubMedPubMedCentral

21.

Paul S, Davis AM. Diagnosis and management of nonalcoholic fatty liver disease. JAMA. 2018;320(23):2474–5. https://doi.org/10.1001/jama.2018.17365.CrossRefPubMed

22.

Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019;16(9):517–30. https://doi.org/10.1038/s41575-019-0169-z.CrossRefPubMed

23.

Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95. https://doi.org/10.1002/hep.20466.CrossRefPubMed

24.

Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8. https://doi.org/10.1016/j.dld.2009.08.002.CrossRefPubMed

25.

Song K, Lee HW, Choi HS, et al. Comparison of the modified TyG indices and other parameters to predict non-alcoholic fatty liver disease in youth. Biology. 2022. https://doi.org/10.3390/biology11050685.CrossRefPubMedPubMedCentral

26.

Park B, Lee HS, Lee YJ. Triglyceride glucose (TyG) index as a predictor of incident type 2 diabetes among nonobese adults: a 12-year longitudinal study of the Korean Genome and Epidemiology Study cohort. Transl Res. 2021;228:42–51. https://doi.org/10.1016/j.trsl.2020.08.003.CrossRefPubMed

27.

Mirr M, Skrypnik D, Bogdański P, Owecki M. Newly proposed insulin resistance indexes called TyG-NC and TyG-NHtR show efficacy in diagnosing the metabolic syndrome. J Endocrinol Invest. 2021;44(12):2831–43. https://doi.org/10.1007/s40618-021-01608-2.CrossRefPubMedPubMedCentral

28.

Rivière B, Jaussent A, Macioce V, et al. The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabetes Metab. 2022;48(4):101345. https://doi.org/10.1016/j.diabet.2022.101345.CrossRefPubMed

29.

Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity: comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51. https://doi.org/10.1210/jc.2010-0288.CrossRefPubMed

30.

Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15–37. https://doi.org/10.4093/dmj.2021.0280.CrossRefPubMed

31.

Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies. Front Endocrinol. 2020;11:597648. https://doi.org/10.3389/fendo.2020.597648.CrossRef

32.

Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):120. https://doi.org/10.1186/s12933-017-0604-9.CrossRefPubMedPubMedCentral

33.

Masarone M, Rosato V, Dallio M, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613. https://doi.org/10.1155/2018/9547613.CrossRefPubMedPubMedCentral

34.

Zhang Y, Li P, Miao M, et al. Nonalcoholic fatty liver disease is associated with increased atrial fibrillation risk in an elderly Chinese population: a cross-sectional study. Biomed Res Int. 2018;2018:5628749. https://doi.org/10.1155/2018/5628749.CrossRefPubMedPubMedCentral

Title: Association between the Triglyceride–Glucose Index and Non-Alcoholic Fatty Liver Disease in patients with Atrial Fibrillation
Authors: Xiaozhong Li
Fenfang Zhan
Tian Peng
Zhen Xia
Juxiang Li
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Atrial Fibrillation
Fatty Liver
Insulins
Insulins
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01188-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association between the Triglyceride–Glucose Index and Non-Alcoholic Fatty Liver Disease in patients with Atrial Fibrillation

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Schisandrin A regulates the Nrf2 signaling pathway and inhibits NLRP3 inflammasome activation to interfere with pyroptosis in a mouse model of COPD

ECMO in adult patients with severe trauma: a systematic review and meta-analysis

Remimazolam tosylate's long-term sedative properties in ICU patients on mechanical ventilation: effectiveness and safety

Arthroscopic Bankart repair versus conservative treatment for first-time traumatic anterior shoulder dislocation: a systematic review and meta-analysis

Association between spinal muscular atrophy type and delayed diagnosis and the risk of spinal deformity in Indonesian patients

The clinical outcomes of xenografts in the treatment of burn patients: a systematic review and meta-analysis